The current PE ratio of VNDA can't be determined, as the TTM EPS of -$0.33 is negative. The last PE ratio of Vanda Pharmaceuticals, recorded in December 2023, was 105.5.
The PE ratio of Vanda Pharmaceuticals has averaged 68.75 over the last ten years. Over the past ten years, VNDA's PE ratio was at its highest in the Jun 2018 quarter at 952.5, when the stock price was $19.05 and the EPS was $0.02. The lowest value was in the Mar 2020 quarter, when it reached 4.75 with a price of $10.36 and an EPS of $2.18.
Maximum annual increase: 304.23% in 2020
Maximum annual decrease: -85.53% in 2019
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | N/A | N/A | $4.79 | -$0.33 |
2023 | 105.5 | 57.04% | $4.22 | $0.04 |
2022 | 67.18 | 156.9% | $7.39 | $0.11 |
2021 | 26.15 | -14.43% | $15.69 | $0.6 |
2020 | 30.56 | 304.23% | $13.14 | $0.43 |
2019 | 7.56 | -85.53% | $16.41 | $2.17 |
2018 | 52.26 | N/A | $26.13 | $0.5 |
2017 | N/A | N/A | $15.2 | -$0.35 |
2016 | N/A | N/A | $15.95 | -$0.41 |
2015 | N/A | N/A | $9.31 | -$0.94 |
2014 | 24.69 | N/A | $14.32 | $0.58 |
2013 | N/A | N/A | $12.41 | -$0.69 |
2012 | N/A | N/A | $3.7 | -$1.01 |
2011 | N/A | N/A | $4.76 | -$0.35 |
2010 | 36.38 | N/A | $9.46 | $0.26 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Dec 2024 | N/A | N/A | $4.79 | -$0.33 |
Sep 2024 | N/A | N/A | $4.69 | -$0.29 |
Jun 2024 | N/A | N/A | $5.65 | -$0.2 |
Mar 2024 | N/A | N/A | $4.11 | -$0.09 |
Dec 2023 | 105.5 | 412.88% | $4.22 | $0.04 |
Sep 2023 | 20.57 | -15.73% | $4.32 | $0.21 |
Jun 2023 | 24.41 | 4.27% | $6.59 | $0.27 |
Mar 2023 | 23.41 | -65.15% | $6.79 | $0.29 |
Dec 2022 | 67.18 | -11.61% | $7.39 | $0.11 |
Sep 2022 | 76 | 46.44% | $9.88 | $0.13 |
Jun 2022 | 51.9 | 51.44% | $10.9 | $0.21 |
Mar 2022 | 34.27 | 31.05% | $11.31 | $0.33 |
Dec 2021 | 26.15 | -5.42% | $15.69 | $0.6 |
Sep 2021 | 27.65 | -24.16% | $17.14 | $0.62 |
Jun 2021 | 36.46 | 40.77% | $21.51 | $0.59 |
Stock name | PE ratio | Market cap |
---|---|---|
MRK Merck & Co Inc | 14 | $239.09B |
PFE Pfizer Inc | 18.82 | $151.49B |
NVS Novartis AG | 19.52 | $228.26B |
JNJ Johnson & Johnson | 28.54 | $401.33B |
LLY ELI LILLY & Co | 73.94 | $824.51B |
BMY Bristol Myers Squibb Co | N/A | $123.97B |
VNDA Vanda Pharmaceuticals Inc | N/A | $282.83M |
The current price to earnings ratio of VNDA can't be calculated, as its EPS of -$0.33 is negative.
The 3-year average PE ratio for VNDA stock is 50.41.
The 5-year average PE ratio for VNDA stock is 36.73.
The highest quarterly PE ratio in the last ten years has been 952.5 and it was in the Jun 2018 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.